Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value
$3.99−0.07 (-1.72%)
Close on Nov 13, 2026Market cap $1.40BP/E –Yield –
Nuvation Bio gross margin
Gross margin is gross profit as a percentage of revenue.
Nuvation Bio's gross margin for the twelve months ending Sep 30, 2025 was 54.3%. For fiscal 2024 it was 10.1%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 10.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | 74.5% | +182.9 |
| Q2 FY2025 | Jun 30, 2025 | 46.7% | +40.6 |
| Q1 FY2025 | Mar 31, 2025 | 32.1% | – |
| Q4 FY2024 | Dec 31, 2024 | 26.2% | – |
| Q3 FY2024 | Sep 30, 2024 | -108.4% | – |
| Q2 FY2024 | Jun 30, 2024 | 6.1% | – |
See a number that looks wrong?